Phage Therapy Market Size, Share, Growth, Trends, Global Industry Analysis By Type (DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage, and Others), By Application (Animal Health, Aquaculture, Agriculture, Food Industry, Human Health, and Others), Regional Insights and Forecast From 2025 To 2033

• 

   Request a Free Sample To Get More Information on this Market

PHAGE THERAPY MARKET REPORT OVERVIEW

The global phage therapy market size was valued at USD 0.04 billion in 2024 and is projected to touch USD 0.16 billion by 2033, exhibiting a CAGR of 17.6% during the forecast period from 2025 To 2033.

Phage Therapy (PT) is also called Bacteriophage therapy (BT). It treats bacterial infections with viruses. Phages or bacteriophages are the names for bacterial viruses. Phages don't damage people, animals, or plants; they only kill germs. Although phage therapy may seem novel, it has been practiced for a century. Bacteriophage research has to be expanded. This treatment for bacteria that cause disease may be a good substitute for antibiotics.

Phase therapy causes germs to explode or lyse, thus eliminating them. This occurs when the virus attaches to the bacteria. By injecting its genes into the bacteria, a virus infects its DNA or RNA. Phage treatment has advantages that compensate for antibiotics' drawbacks. There are various forms of bacteriophages, just as there are various varieties of bacteria. Each type of phage, however, will only attack a certain bacterium. It won't spread to different bacteria. This implies that phages can be employed to specifically target microorganisms that cause illness.

PHAGE THERAPY MARKET SHARE FACT AND FIGURES

Regional Breakdown

• North America holds a 45% market share,USD 0.018 billionwith a 17.2% CAGR, driven by leading research institutes, rising adoption of phage therapy as an alternative to antibiotics, and robust investments in biotechnology and pharmaceuticals.

• Asia-Pacific holds a 35% market share, or USD 0.014 billion in 2024, growing at a 18.0% CAGR, with strong government support for the development of bacteriophage-based treatments, particularly in China, India, and South Korea, which have a rising burden of antimicrobial resistance (AMR).

• Europe captures 15% of the market, or USD 0.006 billion in 2024, growing at 16.3% CAGR, driven by the increasing prevalence of multi-drug resistant infections and growing collaborations between universities and biotech companies in the UK, France, and Germany.

• Rest of the World holds around 5% of the global market, equating to USD 0.002 billion in 2024, growing at 17.0% CAGR, spurred by emerging healthcare sectors and increasing awareness about phage therapy in Latin America, the Middle East, and Africa.

Product Segments Breakdown

• DsDNA Bacteriophage dominates the market with approximately 55% of sales, amounting to about USD 0.022 billion in 2024, with a 17.4% CAGR, due to their high effectiveness in targeting bacterial pathogens and their wide range of applications in clinical settings.

• SsDNA Bacteriophage holds around 25% of the market, or USD 0.01 billion in 2024, growing at 18.2% CAGR, driven by their advantages in genetic manipulation and use in personalized medicine.

• SsRNA Bacteriophage represents 15% of the market, equating to around USD 0.006 billion in 2024, growing at 16.8% CAGR, as they offer unique solutions in combating antibiotic-resistant bacteria and emerging viral infections.

• Others (including phages used in food preservation, agriculture, and other niches) account for 5% of the market, equating to USD 0.002 billion in 2024, with a 17.6% CAGR, reflecting growing research into non-medical uses of phage therapy.

This detailed breakdown highlights the key numbers, growth trends, and factors driving the phage therapy market, emphasizing its significant potential in revolutionizing healthcare treatments.

COVID-19 IMPACT

"Immunity Inducing Prowess Boosted Market Share During Pandemic"

COVID-19 had a life changing impact globally. The global phage therapy market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the global phage therapy market experienced a major boost.

Research papers published on ScienceDirect stated that 8.4% of the total COVID-19 patients are also diagnosed with secondary bacterial infection. They also noticed an inappropriate and excess usage of antibiotics in the COVID treatment which would give rise to antibiotic-resistant organisms. The paper also stated that antibiotic resistance is predicated to be a pandemic by 2050 causing 10 million deaths per year worldwide. This fear, led for doctors to go with phase therapy to treat COVID-19 patients.

The studies have confirmed that in addition to their antibacterial abilities, phage therapy also displays antiviral properties. Phage therapy also shows effectiveness for building immunity against viral pathogens. The therapy reduces the activation of NF kappa B, thereby producing the antiviral protein phagicin. They also upregulated defensin to induce antiviral immunity. Thus, the various beneficial factors of phase therapy over antibiotics caused a boost in the global phase therapy market share.

LATEST TRENDS

"Multipurpose Developments to Benefit Market Prospects"

According to an article on ScienceDirect, the effectiveness of phage therapy has been shown to be effective against a variety of bacterial infections, including Escherichia coli, Pseudomonas species, and Staphylococcus species. As a result, Applications of phage therapy have seen substantial advancement in more general therapeutic settings. Thereby, phages can be applied in a variety of ways, including human antibiotherapy and environmental cleaning. They further established that phase therapy could be used as novel antimicrobial agents to combat antimicrobial resistance and a number of contemporary phage treatment techniques.

National Library of Medicine has stated that phage could be used in clinical laboratories to identify species and subtypes of bacteria. They have established that they are effective against MDR pathogens thus can be used in combination with antibiotics. Their tests have concluded that phase therapy can have little to no effect on the normal microflora. Since, phages simultaneously evolve with their hosts, they can be adapted to latest resistant strains of the host bacterium.

PHAGE THERAPY MARKET SEGMENTATION

By Type

Based on type, the market is divided into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage, and Others. DsDNA Bacteriophage segment is anticipated to hold maximum share during 2032.

By Application

Based on application, the market is bifurcated into Animal Health, Aquaculture, Agriculture, Food Industry, Human Health, and Others. Animal health segment is projected to dominate the market share through 2032.

DRIVING FACTORS

"Harmful Effects of Antibiotics to Boost Demand"

Research papers published on ScienceDirect stated that 74.6% of patients diagnosed with bacterial infections are treated with antibiotics. They also noticed an inappropriate and excess usage of antibiotics in the COVID treatment which would give rise to antibiotic-resistant organisms. The paper also stated that antibiotic resistance is predicated to be a pandemic by 2050 causing 10 million deaths per year worldwide. This fear, led for doctors to go with phase therapy to treat COVID-19 patients.

"Growing Patient Numbers to Boost Market Growth"

Article published on The Lancet stated that an estimated 4.95 million deaths have occurred caused by bacterial AMR in 2019. This death rate was attributed to the resistance of antibiotics. The rate is at 27.3 deaths per 100,000 people. This increasing number in bacterial infection would spike the need for phase therapy. This is also contributed by the negative effects of antibiotics which are causing more infections day by day.

RESTRAINING FACTORS

"Lack of Research to Pose as a Restraining Factor "

There are several factors that could affect the global phase therapy market growth. The growth of the market is mainly refrained from the lack of research. The lack of research associated with the phase therapy is what hinders people’s choice of treatment. Expert analysis is highly required for the treatment of a patient using phase therapy. Therefore, further research is a must to achieve desired result. The lack of awareness of this test also poses as a restraining factor for the growth of this market.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Top Phage Therapy Companies

• NPO Microgen [Russia]
• Proteon Pharmaceuticals [India]
• Phagelux [China]
• Intralytix [U.S.]
• Micreos [Netherlands]
• Eliava BioPreparations [Georgia]
• Locus Biosciences,Inc [U.S.]
• Pharmex Group,LLC [Ukraine]
• Pherecydes Pharma [France]
• APS Biocontrol Ltd [U.K.]
• Qingdao Phagepharm Bio-tech [China]
• Fixed-Phage Limited [U.K.]
• Zeptometrix [U.S.]
• Phage International, Inc [U.S.]
• MicroMir [Russia]
• iNtODEWORLD, Inc [U.S.]
• NEXTBIOTICS [U.S.]
• Armata Pharmaceuticals, Inc [U.S.]
• Innophage [Portugal]
• Adaptive Phage Therapeutics [U.S.]
• TechnoPhage [Portugal]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.